|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 2530 | Drugs / Medical | 01/19/2004
The Federal Trade Commission has filed an enforcement action against marketer QT, Inc. on behalf of all persons who purchased a Q-Ray Bracelet or other similar "ionized" bracelet, alleging that the company has falsely advertised that the bracelets increase athletic ability and reduce joint and muscle pain in violation of the Federal Trade Commission Act. The action seeks disgorgement of all profits made through sales of the bracelets, as well as an order that will prevent the company from claiming that the bracelets have medicinal qualities.
The action alleges that the Illinois-based marketer of the purported pain-relief product deceptively claims that the Q-Ray Bracelet is a fast-acting effective treatment for various types of pain and that tests prove that the Q-Ray Bracelet relieves pain. A recent study conducted by the Mayo Clinic in Jacksonville, Florida, shows that the Q-Ray Bracelet is no more effective than a placebo bracelet at relieving muscular and joint pain. The court has issued a temporary restraining order against the defendants, which prohibits the company from making any misleading or deceptive claims about the Q-Ray Bracelet and freezes the company's assets. The Q-Ray Bracelet is a C-shaped metal bracelet that the company claims is "ionized" through a secret process that gives it pain-relieving abilities. It is promoted through a nationally televised 30-minute infomercial and on the Internet at www.qray.com, www.q-ray.com, and www.bio-ray.com. The company allegedly claims in its ads that its product works by altering the body's positive and negative energy to naturally relieve pain from a variety of ailments, including musculoskeletal pain, sciatica, headaches, tendinitis, and injuries. The Q-Ray Bracelets range in price from $49.95 to $249.95. The company's infomercial advertises a risk-free money back guarantee that allows consumers to return the Q-Ray Bracelet for a full refund within 30 days if they are not satisfied. The action alleges, however, that consumers were not able to readily obtain a full refund of the purchase price if they returned the product within 30 days. Furthermore, the action alleges that some purchasers who viewed the infomercial and went to the defendants' website to order the Q-Ray Bracelet were not given this 30-day satisfaction guarantee. On March 13, 2003, a private class action was also certified in Illinois state court against the company based on similar allegations. The class is composed of all persons who purchased a Q-Ray bracelet or other similar "ionized" bracelet manufactured, distributed, or sold by QT, Inc. since January 1, 1995. Proceedings in that case are currently ongoing. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest Mad Cow Disease is no longer a only foreign phenomenon. A class action has been filed against Quality Food Centers, a subsidiary of Kroger, on behalf Washington citizens who purchased meat that was potentially tainted with mad cow disease, and who allege that the grocery store chain should have used information gathered through its customer loyalty program or in those who purchased the beef. The beef was sold in late December 2003 at approximately 40 stores across Washington under the label of “9% Leanest Ground Beef.” Kahn Gauthier Swick is investigating possible legal actions against nursing homes to recover for injuries suffered by nursing home residents. There are more than one and one-half million elderly and disabled persons in 17,000 nursing homes across the United States. A class action has been filed against Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) and certain of its officers and directors by stockholders who purchased the company's common stock between October 29, 2001, and April 28, 2003.
Several class actions have been filed against the officers and directors of biotechnology company Organogenesis, Inc. (formerly AMEX: ORG) by stockholders who purchased the company's common stock between November 15, 1999, and January 30, 2002. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. A class action has been filed against biopharmaceutical company Titan Pharmaceuticals, Inc. (AMEX: TTP) and certain of its officers and directors by stockholders who purchased the company's common stock between December 1, 1999, and July 22, 2002. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.
Several class actions have been filed against medical information technology systems company IMPAC Medical Systems, Inc. (Nasdaq:IMPCE), and certain of its officers and directors by stockholders who purchased the company's common stock between November 20, 2002, and May 13, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
